International markets and lower RM cost drive earnings Bioscience off-take at a healthy pace ...
Alkem Laboratories Ltd. We have coverage on Alkem Laboratories Ltd with a BUY rating on stock....
Slower domestic growth, US rise not a healthy mix; D/G to SELL Result Synopsis Alkem report...
Alkem Laboratories Limited We have coverage on Alkem Laboratories Ltd with a BUY rating on sto...
Alkem Laboratories manufactures formulations as well as API, has a strong foothold in India and i...
Seasonality drives revenue, price cut hits margin Alkem Laboratories’ (Alkem) ...
Alkem Laboratories is currently trading at Rs. 3369.05, up by 8.05 points or 0.24% from its previ...
Steady performer on growth, margin Result Synopsis Alkem reported an all-round beat with US...
Strong operating leverage drives earnings growth On track to implement cost rationalization measu...
Alkem Laboratories is currently trading at Rs. 3257.05, down by 41.00 points or 1.24 % from its p...
Steps underway to mitigate cost pressures * ALKEM delivered an inline operational performance ...
Presumptive margin recovery baked in; D/G to ADD Result Synopsis Alkem gross margin came in...
Looking beyond near term margin weakness Result Synopsis Alkem margin came in lower than es...
India focused play and encouraging outlook bodes well Given the turmoil on the international f...
Domestic Formulation/non-US segment drives earnings growth Posts market beating growth in Acut...
US rebound key to earnings Our view Alkem lowered US growth expectation and now expects a f...
All round beat Alkem Laboratories’ (Alkem) reported Q1FY22 performance materially above ...
DF outshines for the quarter; US to follow suit shortly Biosimilars in buildup mode * Alkem...
Beneficiary of strong recovery in acute portfolio Alkem Laboratories’ (Alkem) has seen s...
Our view Alkem’s domestic business is set to sustain healthy growth looking beyond the C...
Below is quote on Alkem Laboratories by Mr. Yash Gupta, Equity Rese...
On growth path despite high base of past year * ALKEM is well-placed to benefit from a medium ...
Strong India growth; margins weak Alkem Laboratories’ (Alkem) reported Q4FY21 performanc...
Strong momentum in Domestic Formulations drives earnings New launches to improve US growth pro...
Below are Quote on Alkem Laboratories reported below the market expectation for Q4FY21&nbs...
Result Highlights * Q4 revenues increased by 7% YoY driven by robust India sales (+17% YoY, tr...
Alkem Laboratories is currently trading at Rs. 2714.00, up by 64.90 points or 2.45% from its prev...
Alkem Laboratories is currently trading at Rs. 2647.75, up by 73.45 points or 2.85% from its prev...
Increased opex leads to earnings miss Outlook better for DF as well as US * Alkem Lab (AL...
Q3 FY21 call highlights * Healthy traction in chronic and market share growth in acute seen a...